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Objective: To perform a pharmacoeconomic analysis on the treatment of chronic
obstructive pulmonary disease (COPD) with the addition of tiotropium bromide.
Methods: Pharmacoeconomic modeling was performed utilizing the efficacy of
tiotropium bromide from the literature on different settings and severity of COPD.
Reductions in exacerbations, hospitalizations, and number of exacerbation days per
year were derived from these studies. Cost of drug treatment, exacerbations,
hospitalization, and loss of income were derived from local data in Singapore and
reported in Singapore dollars (US$1 ¼ S$1.71). A model was constructed to calculate
the impact of one-year treatment with tiotropium bromide, and the results were
reported for the total incremental cost per year, cost per year needed to reduce one
hospitalization in one year, and cost-savings from hospitalizations in one year.
Sensitivity analysis were performed for different number of patients treated per
year, differing cost of hospitalization, different cost for tiotropium bromide,
different impact of tiotropium bromide on clinical outcomes, and the different
amount of substitution drug utilized in the comparator group.
Results: Using the different clinical effects and looking at the impact on treating
1000, 2000, and 10,000 patients per year, most of the results showed a high level of
decrease in overall cost per year that ranged from S$145.40 to S$840.37 per patient
treated. Cost per year needed to reduce one hospitalization in one year ranged from
S$3217.31 to S$18,148.92. Cost-savings from hospitalizations in one year per patient
treated ranged from $57.16 to $322.49. This may contribute as high as 83% of the
overall cost saving. Sensitivity analysis supports the cost savings finding.Elsevier Ltd. All rights reserved.
d no financial relationship for the authors.
89060; fax: +65 67794112.
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Table 1 Clinical effects of ti
Casaburi et al.2
FEV1 (% predicted)
Hospitalization events per pati
Exacerbation events per patien
Exacerbation days per patient
Brusasco et al.3
FEV1 (% predicted)
Hospitalization events per pati
Exacerbation events per patien
Exacerbation days per patient
Niewoehner et al.6
FEV1 (% predicted)
Hospitalization events per pati
Exacerbation events per patien
Exacerbation days per patient
FEV1, forced expiratory volume in
Pharmacoeconomic effect of tiotropium bromide in COPD 2191Conclusion: Adding tiotropium bromide for severe COPD patients would lead to a
significant cost savings for the economy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
common condition that leads to frequent hospita-
lizations. It was responsible for 8600 hospital
admissions in 2002 in Singapore, being the eighth
most common cause of admission.1 This led to 570
deaths in 2002, and was the seventh most common
cause of death.1
A new medication, tiotropium bromide, provided
in a HandihalerTM device, has been shown to
improve lung function, improve quality of life and
reduce dyspnea, reduce the number of COPD
exacerbations, and reduce the number of hospita-
lizations in randomized control trials against
placebo.2,3 However, its local usage has been
hampered by the cost which is S$90.60 for 30 doses
of tiotropium bromide. This perceived high drug
acquisition cost has led to different hospitals
limiting the usage of the drug, even though a
recent pharmacoeconomic study in the US setting
concluded that the total healthcare cost minus the
drug acquisition cost would lead to a cost saving of
US$1043 if tiotropium bromide was used in the
treatment for one year.4 The Netherlands and
Belgium study5 which did include the drug acquisi-
tion cost concluded that there was an increased
cost of 180 Euros per patient per year with betterotropium bromide from thr
ent year
t year without hospitalizat
year
ent year
t year without hospitalizat
year
ent year
t year without hospitalizat
year
1 s. NA, not applicable.health outcomes if tiotropium bromide was sub-
stituted for ipratropium bromide.
We have therefore conducted a simple pharma-
coeconomic analysis using local data and cost to
derive a potential result from this new drug.Methods
The clinical benefits of tiotropium bromide in
differing severities of COPD were derived from three
published studies2,3,6 compared to placebo and shown
in Table 1. All cost is shown as Singapore dollars
(current exchange rate to US$ is US$1 ¼ S$1.71).
The hospitalization cost is calculated from the
published data from Singapore’s Ministry of Health
subsidized COPD patients hospitalized between 1
July 2003 and 1 May 2004 for four hospitals (Changi
General Hospital, National University Hospital,
Singapore General Hospital and Tan Tock Seng
Hospital),1 using the average of the median charge
and assuming that there was a 60% subsidy for this
class of patient. Average length of stay was
assumed to be 4.2 days based on the average of
the four hospitals for these patients. The sum was
then assumed to be the cost of each hospitaliza-
tion. In addition to data from the Ministry of
Health, the average cost of hospitalization foree studies.
Tiotropium bromide Placebo
39.1 38.1
0.055 0.094
ion 0.674 0.789
NA NA
11.6 12.1
0.43 0.65
ion 1.04 1.42
17.2 25
36 36
0.177 0.253
ion 0.676 0.798
11.18 14.26
ARTICLE IN PRESS
K.-H. Lee et al.2192COPD patients in the year 2003 was also available
from our cluster (National Healthcare Group)
database (consisting of three hospitals, National
University Hospital, Tan Tock Seng Hospital and
Alexandra Hospital) covering a total of 2104 cases.
Acquisition cost for the drugs are based on the
current cost at National University Hospital. All the
cost assumptions are tabulated in Table 2.
The model was then performed on different
number of patients (1000, 2000 and 5000). Incre-
mental cost per year of tiotropium bromide treat-
ment was calculated by taking the total cost of
using the drug for one year minus the total cost of
ipratropium bromide for one year (substituting the
drugs) minus the reduction in hospitalization cost
for one year minus the reduction in cost of treating
exacerbations minus the reduction in the loss of
income. One assumes that the other treatment
costs are not altered, while one presumes that if
tiotropium bromide is being used, the short-acting
anticholinergic (ipratropium bromide) would be
replaced. Cost to reduce one hospitalization and
the savings in hospitalization cost per year were
also calculated. The percentage of cost savings
from decreasing hospitalization was calculated by
dividing the incremental cost per year of tiotro-
pium bromide treatment by the savings in hospita-
lization cost per year. Sensitivity analysis was
performed to look at the influence of the differing
impact of the drug, different dosing of ipratopium
bromide and the varying cost of hospitalization.
Note that there is no cost provided for improve-
ment in quality of life and reduction in feelings of
dyspnea that is significantly higher in tiotropium
treated patients. There was also no adjustment for
the potential differing cost in hospitalization for
those treated with tiotropium bromide as the
number of days of hospitalization is also reduced
in this group of patients compared to placebo.2,3Results
The results of the different assumptions and effects
utilized from the different studies are shown inTable 2 Cost assumptions for chronic obstructive pulmo
Cost of one year of tiotropium bromide
Cost of one year of ipratropium bromide (8 puffs a day)
Cost of one year of ipratropium bromide (16 puffs a day)
Cost of each exacerbation (A&E visit and drugs)
Cost of each hospitalization (Ministry of Health data)1
Cost of each hospitalization (National Healthcare Group d
Cost of one day of exacerbation/hospitalization causing los
S$, amount shown in Singapore dollars (1 US$ ¼ 1.71 S$).Table 3 (which used Ministry of Health data) and
Table 4 (which used National Healthcare Group
data). These demonstrate significant cost savings in
favor of tiotropium. These apply to the incremental
cost per year of tiotropium bromide treatment, to
the cost savings in hospitalization per year, and to
the cost required to reduce one hospitalization. It
is apparent that the cost savings generally increase
with the number of patients treated with tiotro-
pium bromide per year. In addition, cost savings are
greater in patients with more severe COPD, as
evidenced by the largest calculated savings when
using data from Brusasco et al.3 in which the COPD
was most severe (mean forced expiratory volume in
1 s (FEV1) 11–12% of predicted).
The overall cost savings vary depending on the
cost for hospitalization (Fig. 1), the usage of
ipratropium bromide (Fig. 2), and the potential
different acquisition cost of tiotropium bromide in
other institutions (Fig. 3). The contribution to the
overall cost savings from decreasing hospitalization
costs varies depending on the different clinical
effects of the studies utilized (Casaburi et al.,2
Brusasco et al.3 or Niewoehner et al.6). This varied
from 32% to 72% using Ministry of Health data (Table
3) and from 41% to 79% using National Healthcare
Group data (Table 4). In addition, although no cost
savings were found utilizing data from Niewoehner
et al.6 (note positive rather than negative value for
incremental cost in both Tables 3 and 4), this would
not be the case if the assumed use of ipratropium
bromide was increased from eight doses per day.
E.g. if it were assumed that 16 doses of ipratropium
bromide were used per day, the cost savings for
tiotropium bromide use per year per 1000 patients
will be $145,396.88 using Ministry of Health figures
and $196,649.00 using National Healthcare Group
figures.Discussion
This analysis has demonstrated the potential cost
savings to the healthcare system if tiotropium
bromide is utilized for severe COPD patients. Evennary disease management in Singapore.
S$1102.30 (30 doses for S$90.60)
S$197.25 (200 actuations for S$13.51)
S$394.49 (200 actuations for S$13.51)
S$75.00
S$1465.63
ata) S$2140.00
s of income S$100.00
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Table 3 Cost calculations with tiotropium bromide using international and Singapore’s Ministry of Health data.
Number of
patients treated
with tiotropium
Incremental cost
per year of
tiotropium bromide
treatment
Incremental
cost per year of
tiotropium
bromide
treatment per
patient
Cost to reduce
one
hospitalizationy
Savings in
hospitalization
cost per year
% of savings
from
decreasing
hospitalization
Casaburi et al.2
1000 S$176,751.57 S$176.75 S$18,148.92 S$57,159.57 32.3
2000 S$353,503.14 S$176.75 S$18,148.92 S$114,319.14 32.3
5000 S$883,757.85 S$176.75 S$18,148.92 S$285,797.85 32.3
Brusasco et al.3
1000 S$445,880.60 S$445.88 S$3217.31 S$322,438.60 72.3
2000 S$891,761.20 S$445.88 S$3217.31 S$644,877.20 72.3
5000 S$2,229,403.00 S$445.88 S$3217.31 S$1,612,193.00 72.3
Niewoehner et al.6
1000 S$249,095.12 S$249.10 S$11,908.61 S$111,387.88 Not applicable
2000 S$498,190.24 S$249.10 S$11,908.61 S$222,775.76 Not applicable
5000 S$1,245,475.60 S$249.10 S$11,908.61 S$556,939.40 Not applicable
Based on eight doses of ipratropium bromide a day.
yCost of each hospitalization taken as S$1465.63 based on Ministry of Health data in 2003/4.1
Table 4 Cost calculations with tiotropium bromide using international and Singapore’s national healthcare
group data.
Number of
patients
treated with
tiotropium
Incremental cost
per year of
tiotropium bromide
treatment
Incremental
cost per year of
tiotropium
bromide
treatment per
patient
Cost to reduce
one
hospitalizationy
Savings in
hospitalization
cost per year
% of savings
from
decreasing
hospitalization
Casaburi et al.2
1000 S$203,052.00 S$203.05 S$23,206.51 S$83,460.00 41.1
2000 S$406,104.00 S$203.05 S$23,206.51 S$166,920.00 41.1
5000 S$1,015,260.00 S$203.05 S$23,206.51 S$417,300.00 41.1
Brusasco et al.3
1000 S$594,242.00 S$594.24 S$4113.88 S$470,800.00 79.2
2000 S$1,188,484.00 S$594.24 S$4113.88 S$941,600.00 79.2
5000 S$2,971,210.00 S$594.24 S$4113.88 S$2,354,000.00 79.2
Niewoehner et al.6
1000 S$197,843.00 S$197.84 S$11,908.61 S$162,640.00 Not applicable
2000 S$395,686.00 S$197.84 S$11,908.61 S$325,280.00 Not applicable
5000 S$989,215.00 S$197.84 S$11,908.61 S$813,200.00 Not applicable
Based on eight doses of ipratropium bromide a day.
yCost of each hospitalization taken as S$2140 based on National Healthcare Group data in 2003.
Pharmacoeconomic effect of tiotropium bromide in COPD 2193though there is an increase in cost of acquiring the
drug, the significant clinical benefits, especially in
terms of reduction of hospitalizations, lead to an
overall in cost saving for most of the analysis
performed. It is important to note that there has
been no calculation of the monetary worth ofimproved quality of life in favor of tiotropium
bromide. Our study is consistent with the other two
previous studies4,5 in estimating the benefits of
tiotropium, although it is distinct from the previous
studies because it uses clinical effects from three
different trials with different clinical effects.
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Figure 1 Sensitivity analysis varying the cost of hospitalization, assuming the clinical benefits from the Brusasco et al.3
study, and 16 doses of ipraptropium bromide a day.
Changing the dose of ipratropium per day
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Figure 2 Sensitivity analysis performed by varying the dose of ipratropium bromide used as assumed in the placebo
group, using the clinical effects from the Brusasco et al.3 study, and the cost of S$2140 per hospitalization based on
National Healthcare Group data.
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Figure 3 Sensitivity analysis varying the acquisition cost for tiotropium bromide assuming the clinical effects from the
Brusasco et al.3 study, and the cost of S$2140 per hospitalization based on National Healthcare Group data.
Pharmacoeconomic effect of tiotropium bromide in COPD 2195The US study4 used the data from the Casaburi
et al. study, and did not factor in the cost of
tiotropium bromide and estimated the mean
healthcare total cost per patient was reduced by
US$1043 (1999 valuation) in one year. Furthermore,
they calculated that hospital admission costs were
48% of total direct medical cost. Our study did not
make an allowance for the difference in baseline
medications that was present in the two treated
groups as was done in the US study. For instance,
there were more patients on inhaled corticoster-
oids in the tiotropium-treated group then placebo.
Furthermore, we made the assumption that all our
patients were on anticholinergics and these were
then discontinued when they are treated with
tiotropium, and all the placebo patients would be
taking anticholinergics. In fact, in the Casaburi et
al.3 study, 55% of the tiotropium group and 59% of
the placebo group were taking anticholinergics at
baseline. If we had combination b2-agonist and
anticholinergic (BerodualTM, Boehringer Ingelheim)
as the alternative drug instead, the cost savings
would be even greater as this costs nearly 40% more
than ipratopium bromide alone. The US study also
considered differential hospitalization costs be-
cause of the different days of ICU utilization in
the two groups (0.07 days in the tiotropium
bromide group, and 0.11 days in the placebogroup), but did not factor this into their calcula-
tion. There was also no loss of earnings calculation.
The European study5 utilized the results from a
different trial.7 We did not use the results from this
trial because the difference in the hospitalization
rates was not significantly reduced in the tiotro-
pium bromide group although the trend was a
substantial reduction. The authors from the Eur-
opean study5 included intensive care unit costs that
were separate from the general ward costs, but this
was actually higher amongst the tiotropium bro-
mide-treated group. As this study included the cost
of tiotropium bromide, there was an incremental
cost effectiveness of 667 Euros per exacerbation
avoided.
It is important that the assumptions utilized in
this study and others are fully understood. The
clinical benefit of tiotropium appears to be greatest
in the more severely ill COPD patients measured by
baseline FEV1 measurements as was the case in the
Brusasco et al.3 study. As such, the analysis is
dependent on the clinical effects as documented
under those conditions. The sensitivity analysis on
the cost of tiotropium bromide gives some idea on
its potential impact on cost-savings. It appears that
the beneficial effect is negated as the cost of
tiotropium bromide increases, and if it is more than
S$180 per 30 doses, there appears to be an
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K.-H. Lee et al.2196incremental cost for the beneficial effect rather
than a cost savings. Importantly, the percentage
that is contributed by the hospitalization cost to
the total cost savings varies as the clinical effect
changes. It may be as low as 32% to as high as 79%.
In addition, it should be noted that in our
calculations, it was assumed that other treatment
costs were not altered with the use of tiotropium
bromide. Conceivably, it may be speculated that
with the reduction in hospitalization due to
tiotropium, the burden on the rest of the health-
care system may increase. The impact of this,
however, will likely be small, given that treatment
of COPD with tiotropium decreases not only
hospitalization but also exacerbations and symp-
toms.
It is also useful to consider some of the other cost
studies with other medications utilized in COPD
treatment. Friedman et al.8 looked at the cost
comparison for albuterol versus ipratropium bro-
mide versus albuterol plus ipratropium bromide in
1076 COPD patients with an average FEV1 of 35.1%
over a 85-day period. They showed that there was a
cost benefit advantage based on 1998 prices for
both ipratropium bromide alone (US$113) or ipra-
tropium bromide plus albuterol (US$72) due to
decreased hospitalization costs. A Canadian study9
looking at the effect of the combination inhaler
including ipratropium bromide plus albuterol com-
pared to the drugs given separately also demon-
strated an annual cost savings for the province of
Saskatchewan estimated at about C$103,468 in
favor of the combination inhaler.
This local data will help healthcare managers
make appropriate decisions when considering the
inclusion of tiotropium bromide to their hospital
formularies. It should also provide physicians with
the tools to argue for better treatment for their
COPD patients, and provide cost estimates for the
impact on this new treatment beyond the simple
concern about increased drug expenditures. As
such, our study allows us to draw the conclusion
that tiotropium bromide improves patient’s clinical
outcomes, and still provides a cost-saving for theoverall economy, which is the strongest argument
for its utilization.Conclusion
Tiotropium bromide should be a cost effective
treatment for severe COPD patients leading to
significant cost savings in the Singapore setting.
This finding holds true for the majority of the
sensitivity analysis.References
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